Equities Analysts Issue Forecasts for Penumbra Q1 Earnings

Penumbra, Inc. (NYSE:PEN) – Research analysts at William Blair increased their Q1 2025 earnings estimates for shares of Penumbra in a report released on Thursday, October 31st. William Blair analyst M. Kaczor now anticipates that the company will post earnings per share of $0.79 for the quarter, up from their previous forecast of $0.72. The consensus estimate for Penumbra’s current full-year earnings is $2.58 per share. William Blair also issued estimates for Penumbra’s Q2 2025 earnings at $1.00 EPS.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.16. The company had revenue of $301.04 million for the quarter, compared to analyst estimates of $297.36 million. Penumbra had a net margin of 2.97% and a return on equity of 8.99%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 EPS.

Several other equities research analysts also recently commented on PEN. Morgan Stanley cut their target price on shares of Penumbra from $235.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Robert W. Baird boosted their price target on shares of Penumbra from $244.00 to $248.00 and gave the stock an “outperform” rating in a research report on Thursday. Stifel Nicolaus assumed coverage on shares of Penumbra in a research report on Tuesday, September 17th. They issued a “buy” rating and a $238.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Penumbra in a research report on Thursday. Finally, Truist Financial boosted their price target on shares of Penumbra from $200.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Five equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $226.67.

Penumbra Trading Up 1.9 %

Shares of Penumbra stock opened at $233.30 on Monday. The firm has a market capitalization of $8.95 billion, a PE ratio of 271.28, a price-to-earnings-growth ratio of 2.62 and a beta of 0.51. The company has a current ratio of 5.82, a quick ratio of 3.77 and a debt-to-equity ratio of 0.02. The firm’s 50 day moving average is $200.81 and its 200 day moving average is $193.74. Penumbra has a 1 year low of $148.00 and a 1 year high of $277.34.

Institutional Investors Weigh In On Penumbra

Institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in Penumbra by 111.1% during the third quarter. GAMMA Investing LLC now owns 171 shares of the company’s stock valued at $33,000 after purchasing an additional 90 shares during the last quarter. WASHINGTON TRUST Co purchased a new stake in shares of Penumbra in the second quarter worth about $54,000. Park Place Capital Corp lifted its holdings in shares of Penumbra by 1,473.9% in the third quarter. Park Place Capital Corp now owns 362 shares of the company’s stock worth $70,000 after buying an additional 339 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Penumbra by 1,845.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 389 shares of the company’s stock worth $70,000 after buying an additional 369 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Penumbra in the first quarter worth about $89,000. 88.88% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Penumbra

In other Penumbra news, CEO Adam Elsesser sold 1,620 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $200.00, for a total transaction of $324,000.00. Following the completion of the sale, the chief executive officer now owns 925,962 shares in the company, valued at approximately $185,192,400. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Penumbra news, CEO Adam Elsesser sold 1,620 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $200.00, for a total transaction of $324,000.00. Following the completion of the sale, the chief executive officer now owns 925,962 shares in the company, valued at approximately $185,192,400. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Johanna Roberts sold 600 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $206.22, for a total transaction of $123,732.00. Following the completion of the sale, the executive vice president now owns 61,088 shares of the company’s stock, valued at approximately $12,597,567.36. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,368 shares of company stock worth $6,893,118. 5.00% of the stock is owned by corporate insiders.

Penumbra announced that its Board of Directors has initiated a share repurchase program on Tuesday, August 13th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 2.6% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.